Precision Medicine Proof-of-Concept Study of a TNF Inhibitor in FSGS and Treatment-Resistant Minimal Change Disease
Kidney360. 2024 Nov 18. doi: 10.34067/KID.0000000635. Online ahead of print. ABSTRACT BACKGROUND: Focal segmental glomerulosclerosis (FSGS) and treatment-resistant minimal change disease (TR-MCD) are heterogeneous disorders …